New Delhi: Drug agency Lupin on Monday stated it has launched a generic most cancers therapy treatment within the US. The corporate has launched Dasatinib Tablets in strengths of 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg, within the US, following the approval from the US Meals and Drug Administration (USFDA).
The product was developed in partnership with Pharmascience Inc, it added. Dasatinib Tablets are bioequivalent to Sprycel Tablets of Bristol-Myers Squibb Firm, and indicated for the therapy of the newly identified adults with Philadelphia chromosome-positive (Ph+) persistent myeloid leukemia in persistent part.
As per the IQVIA MAT Oct 2025 gross sales knowledge, Dasatinib Tablets had an estimated annual sale of USD 930 million within the US.
Lupin shares have been buying and selling 0.55 per cent down at Rs 2,126.80 apiece on the BSE.
